why choose us

First received: February 23, 2023

Clinical Trial: Phase 1b Study to Investigate ABBV-CLS-7262's Safety, Tolerability & Pharmacokinetics in Vanishing White Matter Patients

Study Status: Completed

Recruit Status: RECRUITING

Condition: Vanishing White Matter Disease

Study Type: INTERVENTIONAL


Official Title: A Phase 1b Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following ABBV-CLS-7262 Administration in Adult Subjects With Vanishing White Matter Disease

Brief Summary: ABBV-CLS-7262 is an investigational drug being researched for the treatment of Vanishing White Matter disease.This is a 96-week, open-label, single arm study.Subjects will attend regular visits during the course of the study and complete medical assessments, blood tests, checking for side effects, and completing questionnaires.

Read more